Abstract
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Current Pharmaceutical Design
Title:Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Volume: 23 Issue: 18
Author(s): Ivana Stojanovic, Mirjana Dimitrijevic, Marta Vives-Pi, Maria Jose Mansilla, Irma Pujol-Autonell, Silvia Rodríguez-Fernandez, Lenka Palova-Jelínkova, David P. Funda, Alisa Gruden-Movsesijan, Ljiljana Sofronic-Milosavljevic, Catharien M. U. Hilkens, Eva Martinez Caceres and Djordje Miljkovic*
Affiliation:
- Institute for Biological Research "Sinisa Stankovic", Department of Immunology, Despota Stefana 142, 11000 Belgrade,Serbia
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Abstract: Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Export Options
About this article
Cite this article as:
Stojanovic Ivana, Dimitrijevic Mirjana, Vives-Pi Marta, Mansilla Jose Maria, Pujol-Autonell Irma, Rodríguez-Fernandez Silvia, Palova-Jelínkova Lenka, Funda P. David, Gruden-Movsesijan Alisa, Sofronic-Milosavljevic Ljiljana, Hilkens M. U. Catharien, Caceres Martinez Eva and Miljkovic Djordje*, Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170214120708
DOI https://dx.doi.org/10.2174/1381612823666170214120708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P Wave Dispersion and Silent Atrial Fibrillation in Cryptogenic Stroke: The Pathogenic Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Essential Polymers Helping Patients with Obesity
Current Applied Polymer Science Personalizing Medicine from Birth: Are Countries Prepared for the Ethical, Legal, and Social Challenges?
Current Pharmacogenomics and Personalized Medicine Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Psoriasis vulgaris and Psoriasis pustulosa – Epidemiology, Quality of Life, Comorbidities and Treatment
Current Rheumatology Reviews The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Current Pharmaceutical Biotechnology Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry Pyridinoline, A Collagen Crosslink, As a Biochemical Marker for Arthritis
Current Rheumatology Reviews Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Novel Strategies for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Bioactive Herbal Alkaloids as Anti-Infective Agents
Anti-Infective Agents The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal